AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

A-49 Use of Ribavirin in Blood Coagulation Disorder

Technology Application: ΓùÅ To reduce the dosage of procoagulants for blood coagulation disorder patients. .ΓùÅ Could be used as a coagulator during surgical operations to reduce a bleed. .ΓùÅ Could be used as a coagulator to prevent and stop bleeds caused by some diseases.

Detailed Technology Description: Ribavirin has already been approved by the FDA and is regularly used for the treatment of chronic Hepatitis C. Researchers also discovered the Ribavirin application induced more mRNA expression of coagulation factor VII (F-VII, Proconvertin) in human hepatic parenchymal cell line. In addition, they discovered the concentration of other coagulation factors such as Fibrinogen (F-I), Prothrombin (F-II) and Proaccelerin (F-V) increased during this therapy. These increments of coagulation factors are thought to cause the decrement of procoagulants dosage during the treatment of Hepatitis C. The acceleration or improvement of blood coagulation by Ribavirin could help patients reduce their daily procoagulants applications. .

Supplementary Information: Inventor: HONDA, Takashi | TAKAMATSU, Junki | TOYODA, Hidenori | YAMAMOTO, Koji | GOTO, Hidemi
Priority Number: WO2007099652A1
IPC Current: A61K00317056 | A61P000704 | C07H0019052 | C07H0019056
Assignee Applicant: National University Corporation Nagoya University
Title: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BLOOD CLOTTING DISORDER | COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU TROUBLE DE LA COAGULATION
Usefulness: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BLOOD CLOTTING DISORDER | COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU TROUBLE DE LA COAGULATION
Summary: For preventing/treating blood coagulation disorder, bleeding which is associated with deficiency of coagulation factor VII, viral infections disease caused by hepatitis C virus (HCV) or human immunodeficiency virus (HIV), and hemophilia A and B (all claimed).
Novelty: Pharmaceutical composition useful for treating blood coagulation disorder associated with factor VII deficiency, preferably hemophilia, comprises purine nucleoside derivative

Industry: Disease Diagnostic/Treatment

Sub Category: HIV

*Abstract: Researchers studying hemophiliacs suffering from chronic Hepatitis C found that Ribavirin surprisingly decreased the necessary dosage of procoagulants.

Country/Region: USA

For more information, please click Here